Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

SHANGHAI JUNSHI BIOSCIENCES CO., LTD.*
上海君實生物醫藥科技股份有限公司

(a joint stock company incorporated in the People's Republic of China with limited liability)

(Stock code: 1877)

VOLUNTARY ANNOUNCEMENT – NEW INDICATION OF TUOYI® HAS BEEN INCLUDED IN THE NATIONAL REIMBURSEMENT DRUG LIST

This announcement is made by Shanghai Junshi Biosciences Co., Ltd.* (上海君實生物醫藥科技股份有限公司) (the "**Company**") on a voluntary basis. Reference is also made to the overseas regulatory announcement of the Company dated 16 November 2026.

The board (the "**Board**") of directors (the "**Directors**") of the Company is pleased to announce that the Company's product Toripalimab Injection (trade name: TUOYI®, product code: JS001), in combination with disitamab vedotin for the indication of the treatment of HER2-expressing locally advanced or metastatic urothelial carcinoma, was successfully included in Category B of the National Drug List for Basic Medical Insurance, Maternity Insurance and Work-Related Injury Insurance (Year 2026) (the "**NRDL**"). The new edition of the NRDL will officially come into effect on 1 January 2027.

As of the date of this announcement, all 13 indications of TUOYI® approved for marketing in Chinese Mainland have been included in the NRDL. TUOYI® is the only anti-PD-1 monoclonal antibody in the NRDL for the treatment of triple-negative breast cancer ("**TNBC**"), melanoma, first-line renal cell carcinoma and first-line urothelial carcinoma.

ABOUT TUOYI®

Drug name: Toripalimab Injection
Classification of registration: Therapeutic biological product
Class of drug: Antineoplastic drug and immune modulator – monoclonal antibody and antibody drug conjugates -PD-1/PD-L1 inhibitor
Class of medical insurance: Category B
Dosage form: Injection

Indications: 1. Treatment for unresectable or metastatic melanoma after failure of standard systemic therapy; 2. First-line treatment of unresectable or metastatic melanoma; 3. Treatment for locally advanced or metastatic urothelial carcinoma that failed platinum-containing chemotherapy or progressed within 12 months of neoadjuvant or adjuvant platinum-containing chemotherapy; 4. Treatment for recurrent/metastatic nasopharyngeal carcinoma ("**NPC**") after failure of at least two lines of prior systemic therapy; 5. In combination with cisplatin and gemcitabine as the first-line treatment for patients with locally recurrent or metastatic NPC; 6. In combination with paclitaxel and cisplatin as the first-line treatment for patients with unresectable locally advanced/recurrent or metastatic esophageal squamous cell carcinoma; 7. In combination with pemetrexed and platinum as the first-line treatment in epidermal growth factor receptor (EGFR) mutation-negative and anaplastic lymphoma kinase (ALK) mutation-negative, unresectable, locally advanced or metastatic non-squamous non-small cell lung cancer ("**NSCLC**"); 8. In combination with platinum-containing chemotherapy as perioperative treatment and subsequently, monotherapy as adjuvant therapy for the treatment of adult patients with resectable stage IIIA-IIIB NSCLC; 9. In combination with axitinib for the first-line treatment of patients with medium to high risk unresectable or metastatic renal cell carcinoma; 10. In combination with etoposide plus platinum for the first-line treatment of extensive-stage small cell lung cancer (ES-SCLC); 11. In combination with paclitaxel for injection (albumin-bound) for the first-line treatment of recurrent or metastatic TNBC with a well-validated test to evaluate PD-L1 positive (CPS ≥ 1); 12. In combination with bevacizumab for the first-line treatment of unresectable or metastatic hepatocellular carcinoma patients; 13. In combination with disitamab vedotin for the treatment of HER2-expressing locally advanced or metastatic urothelial carcinoma. Among the indications above, item 13 is the new indication included in the NRDL.
Validity period: From 1 January 2027 to 31 December 2027

Toripalimab injection is the first domestic anti-PD-1 monoclonal antibody approved for marketing in China, and has won the "Chinese Patent Gold Award (中國專利金獎)", the top award in China's patent field. In December 2020, toripalimab injection was successfully negotiated into the NRDL for the first time. As of the date of this announcement, all of its 13 indications approved in Chinese Mainland have been included in the NRDL, making it the only anti-PD-1 monoclonal antibody in the NRDL for the treatment of TNBC, melanoma, first-line renal cell carcinoma and first-line urothelial carcinoma.

In terms of international layout, as of the date of this announcement, toripalimab achieved presence in six continents across the world. It has been approved for marketing in over 50 countries and regions worldwide, such as China, the United States and the European Commission, and its marketing applications have been submitted/accepted in various countries and regions.

IMPACTS ON THE COMPANY AND RISK WARNING

The inclusion of the new indication of TUOYI® in the NRDL demonstrated the National Healthcare Security Administration's (the "**NHSA**") recognition of the clinical value, benefit to patients and novelty of TUOYI®, highlighting the state's emphasis on and support for the R&D and industrialization of drugs by local innovative pharmaceutical enterprises.

The results of this negotiation on NRDL will help the Company to further improve the affordability and accessibility of TUOYI® for patients, and will be conducive to further promoting the marketing of commercialized products and enhancing the sales scale, thus having a positive impact on the long-term development of the Company. The Company will actively work with relevant parties to implement the related medical insurance and reimbursement policies, promote the accessibility of the drug to hospitals with continuous efforts, and expand the coverage of core markets and other markets, with a view to constantly enhancing the accessibility of medicines to patients. Details of medical insurance reimbursement and other relevant information shall be subject to the information published by the NHSA and other relevant government departments. Investors are advised to make cautious decisions and pay careful attention to investment risks.

By order of the Board
Shanghai Junshi Biosciences Co., Ltd.*
Mr. Xiong Jun
Chairman

Shanghai, the PRC, 16 November 2026

As at the date of this announcement, the Board of Directors of the Company comprises Mr. Xiong Jun, Dr. Li Ning, Dr. Zou Jianjun, Mr. Li Cong, Mr. Zhang Zhuobing, Dr. Wang Gang and Dr. Li Xin as executive Directors; Dr. Yao Sheng and Mr. Tang Yi as non-executive Directors; and Dr. Feng Xiaoyuan, Mr. Li Zhongxian, Ms. Lu Kun, Dr. Yang Jin and Mr. Chen Liang as independent non-executive Directors.

* *For identification purpose only*